Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIDA: Ontamalimab Long-term Extension in UC and CD
NCT03283085Phase 3Completed
- Sponsor
- Takeda
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 37
01
Overview
A Phase 3 trial of ontamalimab in ulcerative colitis (UC), Crohn's disease, sponsored by Takeda. Started Feb 2018; status: completed.
02
Drugs
ontamalimab
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT03283085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283085.